深圳华药康明

Huayao Kangming is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the development of next-generation oncolytic virus therapies for cancer. The company's core technology platform focuses on engineered oncolytic vaccinia viruses (OVV) designed to selectively replicate in and destroy tumor cells while stimulating a systemic anti-tumor immune response. Its lead candidate, KM1, is a genetically modified vaccinia virus currently undergoing clinical evaluation for the treatment of advanced solid tumors. Huayao Kangming aims to address unmet medical needs in oncology through innovative viral engineering and immunotherapy combinations. The company has secured significant venture capital funding to advance its pipeline through early-stage clinical trials. By leveraging its proprietary OVV platform, the company seeks to overcome the limitations of traditional oncolytic viruses, such as poor systemic delivery and limited immune activation.